
The approval gives adults with polymyalgia rheumatica who struggle with corticosteroids a new treatment option, following positive Phase III results.
The FDA approved Novartis’ Cosentyx for adults with polymyalgia rheumatica (PMR) who have not responded adequately to corticosteroids or cannot tolerate tapering them. Novartis said it is the first anti-IL-17 biologic approved in the United States for PMR.
In the Phase III REPLENISH trial, 40.5% of patients taking Cosentyx 150 mg achieved sustained remission at week 52, compared with 20.5% on placebo. Both groups followed a 24-week steroid-tapering regimen.
Serious adverse events occurred in 15.9% of the Cosentyx group and 14.2% of the placebo group. Novartis reported one fatal case of cryptococcal meningitis in a patient treated with Cosentyx.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.